Therefore, the lack of complete recovery of CD161+ CD4+ T cells in peripheral blood, despite initiation of ART at the earliest possible stage, could contribute to the susceptibility to bacterial infections seen in ART-treated individuals [44,45,46]. The gene discussed is KLRB1; the disease is bacterial infectious disease.